Larry D Morrison

US Patent:

20120065085, Mar 15, 2012

Filed:

May 10, 2011

Appl. No.:

13/068451

Inventors:

Ekaterina Pestova - Glenview IL, US
Larry Morrison - Oro Valley AZ, US
Jesse S. Voss - Rochester MN, US
Lisa M. Peterson - Rochester MN, US
Kevin C. Halling - Rochester MN, US

Assignee:

Abbott Laboratories - Abbott Park IL

International Classification:

C40B 30/04
C40B 40/06
C12Q 1/68

US Classification:

506 9, 435 611, 506 16

Abstract:

The methods and compositions described herein address the need for diagnostic method that could be offered to women during yearly checkups to allow for early detection, diagnosis and classification, and treatment of endometrial cancer. In addition, these methods and compositons addresse the current need for improving diagnostic accuracy of biopsy procedures in symptomatic patients.

US Patent:

20120141987, Jun 7, 2012

Filed:

Jul 14, 2011

Appl. No.:

13/182774

Inventors:

Larry E. Morrison - Oro Valley AZ, US
Irina A. Sokolova - Villa Park IL, US
Steven A. Seelig - Elmhurst IL, US
Kevin C. Halling - Rochester MN, US

International Classification:

G01N 21/64
C12Q 1/68

US Classification:

435 611

Abstract:

Probe sets and methods of using probes and probe sets for the detection of cancer are described. Methods for detecting cancer that include hybridizing a set of chromosomal probes to a biological sample obtained from a patient, and identifying if cancer cells are present the sample. Also included are methods of selecting a combination of probes for the detection of cancer.

US Patent:

20120164626, Jun 28, 2012

Filed:

Oct 24, 2011

Appl. No.:

13/279947

Inventors:

Irina A. Sokolova - Villa Park IL, US
Steven A. Seelig - Elmhurst IL, US
Larry E. Morrison - Oro Valley AZ, US
Walter King - Dover NH, US

Assignee:

VYSIS, INC. - Downers Grove IL

International Classification:

C12Q 1/70
C12Q 1/68

US Classification:

435 5, 435 611

Abstract:

Methods of using probes and probe sets for the detection of high grade dysplasia and carcinoma in cervical cells are described. Methods of the invention include hybridizing one or more chromosomal probes to a biological sample obtained from a subject and detecting the hybridization pattern of the chromosomal probes to the sample to determine whether the subject has high grade dysplasia or carcinoma. Methods of the invention also include preliminary screening the cells for a marker associated with a risk for cancer, and preferably involves screening for HPV infected cells by in situ hybridization using an HPV probe mixture.

US Patent:

20130022970, Jan 24, 2013

Filed:

Jul 9, 2010

Appl. No.:

13/382443

Inventors:

Larry E Morrison - Oro Valley AZ, US
John Coon - Oak Park IL, US

International Classification:

C12Q 1/68
G01N 21/64

US Classification:

435 611

Abstract:

Gene copy numbers of signaling components downstream of EGFR identify non-small cell lung cancer (NSCLC) patients with poor outcomes on 2nd/3rd line gefitinib therapy.

US Patent:

20130034853, Feb 7, 2013

Filed:

Apr 20, 2011

Appl. No.:

13/640301

Inventors:

Brian Kelly - Tucson AZ, US
Hiro Nitta - Oro Valley AZ, US
Thomas Grogan - Tucson AZ, US
Larry Morrison - Oro Valley AZ, US

International Classification:

G01N 21/76

US Classification:

435 611, 436501

Abstract:

The present invention relates to systems and processes for chromogenic in situ hybridization (CISH), and in particular to methods that prevent interference between two or more color detection systems in a single assay. The present invention also relates to processes for scoring assays utilizing break-apart probes.

US Patent:

20130171638, Jul 4, 2013

Filed:

Dec 20, 2012

Appl. No.:

13/721081

Inventors:

ABBOTT MOLECULAR INC. - Des Plaines IL, US
Larry Morrison - Oro Valley AZ, US
Ekaterina Pestova - Glenview IL, US
Irina Sokolova - Villa Park IL, US

Assignee:

ABBOTT MOLECULAR INC. - Des Plaines IL

International Classification:

C12Q 1/68

US Classification:

435 611

Abstract:

A method to detect prostate cancer comprising contacting a sample of prostate cells from the patient with a set of detectably labeled probes under hybridization conditions and determining the presence of chromosomal abnormalities in prostate tumor tissue, PIN (intra-epithelial neoplasia), histologically benign tissue and benign prostatic hyperplasia (BPH); a method to combine immunofluorescence and FISH (IF-FISH) to facilitate the assessment of chromosomal abnormalities; a set of probes; and a kit comprising the set of probes and instructions for diagnosing prostate cancer in a patient.

US Patent:

20130189680, Jul 25, 2013

Filed:

Jan 18, 2013

Appl. No.:

13/744504

Inventors:

Brian D. Kelly - Tucson AZ, US
Jerome W. Kosmeder - Tucson AZ, US
Larry Morrison - Oro Valley AZ, US
Christopher Bieniarz - Tucson AZ, US

Assignee:

VENTANA MEDICAL SYSTEMS, INC. - Tucson AZ

International Classification:

G01N 1/30

US Classification:

435 611, 435 405, 435 79

Abstract:

Disclosed embodiments concern a composition comprising DAB chromogen, and/or derivative thereof, a stabilizer, and polymer capable of preventing or reducing DAB precipitation relative to a composition that does not comprise the polymer. Also disclosed herein is a method for using the disclosed composition and embodiments of a kit.

US Patent:

20130260379, Oct 3, 2013

Filed:

Mar 22, 2013

Appl. No.:

13/849160

Inventors:

William Day - Tucson AZ, US
Mark Lefever - Oro Valley AZ, US
Larry Morrison - Oro Valley AZ, US
Anne M. Pedata - Tucson AZ, US
Stacey Stanislaw - Tucson AZ, US

Assignee:

Ventana Medical Systems, Inc. - Tucson AZ

International Classification:

G01N 33/58

US Classification:

435 611, 435 79

Abstract:

Disclosed herein are embodiments of a signaling conjugate, embodiments of a method of using the signaling conjugates, and embodiments of a kit comprising the signaling conjugate. The disclosed signaling conjugate comprises a latent reactive moiety and a chromogenic moiety that may further comprise a linker suitable for coupling the latent reactive moiety to the chromogenic moiety. The signaling conjugate may be used to detect one or more targets in a biological sample and are capable of being covalently deposited directly on or proximally to the target. Particular disclosed embodiments of the method of using the signaling conjugate comprise multiplexing methods.